Treats active duodenal ulcer. ANDA 75651, held by Sagent. Famotidine.
As of Nov 15, 2026, ANDA 75651 (Famotidine), held by Sagent, was first approved by FDA on Apr 16, 2001, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Famotidine Injection, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. Famotidine Injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions: Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2001 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Famotidine10MG/ML · injectable;injection | Famotidine | Rx |
| Sep 9, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 3, 2008 | Supplement 6Labeling | Approved | None posted |
| Apr 16, 2001 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
